Download Complimentary Report Summary

Bridge the structural, cultural, process and communications gaps between R&D and marketing in early-stage drug development

Early-stage product commercialization continues to challenge even the most skilled and highly respected marketing and drug-development organizations. Changing government regulations, pharmacoeconomics, health care practices, and scientific innovations have transformed the drug-development landscape in the past decade. As patent protection narrows on many companies' top-selling brands, the race to market profitable products in record time is intensifying. These transformations have been met concurrently with rising drug-development costs and diminishing R&D productivity.

These business drivers require organizational and cultural changes within drug companies in order to unite R&D and marketing - and to direct them toward shared objectives early in development. Injecting market input into drug discovery and early clinical development enables marketing and R&D to focus limited resources on the most promising drug candidates. With market information, R&D can develop drug target libraries and hone in on endpoints with the greatest likelihood of fulfilling unmet medical needs. Ultimately, a continuous exchange of information between R&D and marketing enables companies to make more informed portfolio decisions, to serve their markets better, and to achieve higher profits.

This report covers the critical areas in which R&D and marketing need to work together, including portfolio planning, resource allocation, product hand-offs and ownership, and project and product team structures. Best practices and case studies illustrate numerous tools, tactics, organizational structures and strategies used by top-performing pharmaceutical and biotech companies to bridge the gaps between R&D and marketing in early-stage drug development.

Call Adam Bianchi  at 919-403-6583 to get your own copy of "Uniting R&D and Marketing" today.